Transdermal drug delivery systems are the most preferred methods of delivering pruritus drugs.
The majority of the pruritus drugs are available in semi-solid topical dosage forms, such as lotions, gels, and creams, which are easier to apply, are less painful, and provides faster action than other forms of drug delivery methods. Moreover, transdermal drug delivery systems increase the bioavailability of active ingredients and prevent destructive hepatic first-pass metabolism. However, the delivery of small and lipophilic drugs is difficult through the method of drug development.

Market Analysis and Insights: Global Pruritus Drugs Market
The global Pruritus Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pruritus Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pruritus Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pruritus Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pruritus Drugs market.

Global Pruritus Drugs Scope and Market Size
Pruritus Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pruritus Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Topical
Oral
Parenteral

Segment by Application
Hematologic Pruritus
Oncological Pruritus
Renal Pruritus
Endocrine Pruritus
Cholestatic Pruritus

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Allergan Plc
Astellas Pharma Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi